SPARC and DNA methylation: Possible diagnostic and therapeutic implications in gastrointestinal cancers

Cancer Letters

Volumn 328, Issue 1, 2013, Pages 10-17

  Nagaraju, Ganji Purnachandra ^a   El Rayes, Bassel F ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

CpG island methylation; DNA methylation; DNA methyltransferases; Gastrointestinal cancer; SPARC

Indexed keywords

EID: 84868451906     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2012.08.028     Document Type: Review

References (145)

1. Mathis K., Larson D., Dozois E., Cima R., Huebner M., Haddock M., Wolff B., Nelson H., Pemberton J. Outcomes following surgery without radiotherapy for rectal cancer. Br. J. Surg. 2012, 99:137-143.
2. Weiser M.R., Gönen M., Chou J.F., Kattan M.W., Schrag D. Predicting survival after curative colectomy for cancer: individualizing colon cancer staging. J. Clin. Oncol. 2011, 29:4796-4802.
3. Rollins K., Peters C., Safranek P., Ford H., Baglin T., Hardwick R. Venous thromboembolism in oesophago-gastric carcinoma: incidence of symptomatic and asymptomatic events following chemotherapy and surgery. Eur. J. Surg. Oncol. 2011, 37:1072-1077.
4. Garland S.N., Pelletier G., Lawe A., Biagioni B.J., Easaw J., Eliasziw M., Cella D., Bathe O.F. Prospective evaluation of the reliability, validity, and minimally important difference of the functional assessment of cancer therapy-gastric (FACT-Ga) quality-of-life instrument. Cancer 2011, 117:1302-1312.
5. Oka S., Tanaka S., Kanao H., Ishikawa H., Watanabe T., Igarashi M., Saito Y., Ikematsu H., Kobayashi K., Inoue Y. Mid-term prognosis after endoscopic resection for submucosal colorectal carcinoma: summary of a multicenter questionnaire survey conducted by the colorectal endoscopic resection standardization implementation working group in Japanese Society for Cancer of the Colon and Rectum. Dig. Endosc. 2011, 23:190-194.
6. Yi J.M., Dhir M., Guzzetta A.A., Iacobuzio-Donahue C.A., Heo K., Yang K.M., Suzuki H., Toyota M., Kim H.M., Ahuja N. DNA methylation biomarker candidates for early detection of colon cancer. Tumor Biol. 2012, 1:1-10.
7. Sceusi E.L., Loose D.S., Wray C.J. Clinical implications of DNA methylation in hepatocellular carcinoma. HPB 2011, 13:369-376.
8. Baylin S.B. Resistance, epigenetics and the cancer ecosystem. Nat. Med 2011, 17:288-289.
9. Hou P., Liu D., Xing M. Genome-wide alterations in gene methylation by the BRAF V600E mutation in papillary thyroid cancer cells. Endocr. Relat. Cancer 2011, 18:687-697.
10. Tajerian M., Alvarado S., Millecamps M., Dashwood T., Anderson K.M., Haglund L., Ouellet J., Szyf M., Stone L.S. DNA methylation of SPARC and chronic low back pain. Mol. Pain 2011, 7:65-74.
11. Grönniger E., Weber B., Heil O., Peters N., Stäb F., Wenck H., Korn B., Winnefeld M., Lyko F. Aging and chronic sun exposure cause distinct epigenetic changes in human skin. PLoS Genet. 2010, 6:e1000971.
12. Deshmukh R.S., Østrup O., Østrup E., Vejlsted M., Niemann H., Lucas-Hahn A., Petersen B., Li J., Callesen H., Hyttel P. DNA methylation in porcine preimplantation embryos developed in vivo and produced by in vitro fertilization, parthenogenetic activation and somatic cell nuclear transfer. Epigenetics 2011, 6:177-187.
13. Orta M.L., Domínguez I., Pastor N., Cortés F., Mateos S. The role of the DNA hypermethylating agent Budesonide in the decatenating activity of DNA topoisomerase II. Mutat. Res. 2010, 694:45-52.
14. Taberlay P.C., Jones P.A. DNA methylation and cancer. Epigenet. Disease 2011, 67:1-23.
15. Suzuki M.M., Bird A. DNA methylation landscapes: provocative insights from epigenomics. Nat. Rev. Genet. 2008, 9:465-476.
16. Ueki T., Toyota M., Sohn T., Yeo C.J., Issa J.P.J., Hruban R.H., Goggins M. Hypermethylation of multiple genes in pancreatic adenocarcinoma. Cancer Res. 2000, 60:1835-1839.
17. Fukushima N., Sato N., Sahin F., Su G., Hruban R., Goggins M. Aberrant methylation of suppressor of cytokine signalling-1 (SOCS-1) gene in pancreatic ductal neoplasms. Br. J. Cancer 2003, 89:338-343.
18. Jansen M., Fukushima N., Rosty C., Walter K., Altink R., van Heek T., Hruban R., Offerhaus J.G., Goggins M. Aberrant methylation of the 5'CpG island of TSLC1 is common in pancreatic ductal adenocarcinoma and is first manifest in high-grade PanINs. Cancer Biol. Ther. 2002, 1:293-299.
19. Sato N., Fukushima N., Maehara N., Matsubayashi H., Koopmann J., Su G.H., Hruban R.H., Goggins M. SPARC/osteonectin is a frequent target for aberrant methylation in pancreatic adenocarcinoma and a mediator of tumor-stromal interactions. Oncogene 2003, 22:5021-5030.
20. Matsubayashi H., Canto M., Sato N., Klein A., Abe T., Yamashita K., Yeo C.J., Kalloo A., Hruban R., Goggins M. DNA methylation alterations in the pancreatic juice of patients with suspected pancreatic disease. Cancer Res. 2006, 66:1208-1217.
21. Nagai H., Naka T., Terada Y., Komazaki T., Yabe A., Jin E., Kawanami O., Kishimoto T., Konishi N., Nakamura M. Hypermethylation associated with inactivation of the SOCS-1 gene, a JAK/STAT inhibitor, in human hepatoblastomas. J. Human Genet. 2003, 48:65-69.
22. Muller H.M., Oberwalder M., Fiegl H., Morandell M., Goebel G., Zitt M., Muhlthaler M., Ofner D., Margreiter R., Widschwendter M. Methylation changes in faecal DNA: a marker for colorectal cancer screening?. Lancet 2004, 363:1283-1285.
23. Fukushima N., Walter K.M., Uek T., Sato N., Matsubayashi H., Cameron J.L., Hruban R.H., Canto M., Yeo C.J., Goggins M. Diagnosing pancreatic cancer using methylation specific PCR analysis of pancreatic juice. Cancer Biol. Ther. 2003, 2:78-83.
24. Klump B., Hsieh C.J., Nehls O., Dette S., Holzmann K., Kiesslich R., Jung M., Sinn U., Ortner M., Porschen R., Gregor M. Methylation status of p14ARF and p16INK4a as detected in pancreatic secretions. Br. J. Cancer 2003, 88:217-222.
25. Yan L., McFaul C., Howes N., Leslie J., Lancaster G., Wong T., Threadgold J., Evans J., Gilmore I., Smart H., Lombard M., Neoptolemos J., Greenhalf W. Molecular analysis to detect pancreatic ductal adenocarcinoma in high-risk groups. Gastroenterology 2005, 128:2124-2130.
26. Sproul D., Nestor C., Culley J., Dickson J.H., Dixon J.M., Harrison D.J., Meehan R.R., Sims A.H., Ramsahoye B.H. Transcriptionally repressed genes become aberrantly methylated and distinguish tumors of different lineages in breast cancer. Proc. Natl. Acad. Sci. 2011, 108:4364-4369.
27. Szyf M., Avraham-Haetzni K., Reifman A., Shlomai J., Kaplan F., Oppenheim A., Razin A. DNA methylation pattern is determined by the intracellular level of the methylase. Proc. Natl. Acad. Sci. 1984, 81:3278-3282.
28. Weaver I.C.G., Cervoni N., Champagne F.A., D'Alessio A.C., Sharma S., Seckl J.R., Dymov S., Szyf M., Meaney M.J. Epigenetic programming by maternal behavior. Nat. Neuro. Sci. 2004, 7:847-854.
29. Szyf M. Epigenetics, DNA methylation, and chromatin modifying drugs. Annu. Rev. Pharmacol. Toxicol. 2009, 49:243-263.
30. Jin B., Li Y., Robertson K.D. DNA methylation. Genes Cancer 2011, 2:607-617.
31. Goll M.G., Kirpekar F., Maggert K.A., Yoder J.A., Hsieh C.L., Zhang X., Golic K.G., Jacobsen S.E., Bestor T.H. Methylation of tRNAAsp by the DNA methyltransferase homolog Dnmt2. Science 2006, 311:395-398.
32. Costello J.F., Plass C. Methylation matters. J. Med. Genet. 2001, 38:285-303.
33. Bourc'his D., Xu G.L., Lin C.S., Bollman B., Bestor T.H. Dnmt3L and the establishment of maternal genomic imprints. Science 2001, 294:2536-2539.
34. Singal R., Ginder G.D. DNA methylation. Blood 1999, 93:4059-4070.
35. Missiaglia E., Donadelli M., Palmieri M., Crnogorac-Jurcevic T., Scarpa A., Lemoine N.R. Growth delay of human pancreatic cancer cells by methylase inhibitor 5-aza-2'-deoxycytidine treatment is associated with activation of the interferon signalling pathway. Oncogene 2005, 24:199-211.
36. An H.J., Lee H., Paik S.G. Silencing of BNIP3 results from promoter methylation by DNA methyltransferase 1 induced by the mitogen-activated protein kinase pathway. Mol. Cells 2011, 31:579-583.
37. Chik F., Szyf M. Effects of specific DNMT gene depletion on cancer cell transformation and breast cancer cell invasion; toward selective DNMT inhibitors. Carcinogenesis 2011, 32:224-232.
38. Wang X., Lau K., So L., Lam Y.W. CHD5 is down-regulated through promoter hypermethylation in gastric cancer. J. Biomed. Sci. 2009, 16:95-100.
39. Chuang J.C., Yoo C.B., Kwan J.M., Li T.W.H., Liang G., Yang A.S., Jones P.A. Comparison of biological effects of non-nucleoside DNA methylation inhibitors versus 5-aza-2'-deoxycytidine. Mol. Cancer Ther. 2005, 4:1515-1520.
40. Law A., Lai K.P., Ip C.K.M., Wong A.S.T., Wagner G.F., Wong C.K.C. Epigenetic and HIF-1 regulation of stanniocalcin-2 expression in human cancer cells. Exp. Cell Res. 2008, 314:1823-1830.
41. Stewart D., Donehower R., Eisenhauer E., Wainman N., Shah A., Bonfils C., MacLeod A., Besterman J., Reid G. A phase I pharmacokinetic and pharmacodynamic study of the DNA methyltransferase 1 inhibitor MG98 administered twice weekly. Ann. Oncol. 2003, 14:766-774.
42. Lee B.H., Yegnasubramanian S., Lin X., Nelson W.G. Procainamide is a specific inhibitor of DNA methyltransferase 1. J. Biol. Chem. 2005, 280:40749-40756.
43. Rhee I., Bachman K.E., Park B.H., Jair K.W., Yen R.W.C., Schuebel K.E., Cui H., Feinberg A.P., Lengauer C., Kinzler K.W. DNMT1 and DNMT3b cooperate to silence genes in human cancer cells. Nature 2002, 416:552-556.
44. Mutze K., Langer R., Schumacher F., Becker K., Ott K., Novotny A., Hapfelmeier A., Höfler H., Keller G. DNA methyltransferase 1 as a predictive biomarker and potential therapeutic target for chemotherapy in gastric cancer. Eur. J. Cancer 2011, 47:1817-1825.
45. Jung Y., Park J., Kim T.Y., Park J.H., Jong H.S., Im S.A., Robertson K.D., Bang Y.J. Potential advantages of DNA methyltransferase 1 (DNMT1)-targeted inhibition for cancer therapy. J. Mol. Med. 2007, 85:1137-1148.
46. Yoo C.B., Chuang J.C., Byun H.M., Egger G., Yang A.S., Dubeau L., Long T., Laird P.W., Marquez V.E., Jones P.A. Long-term epigenetic therapy with oral zebularine has minimal side effects and prevents intestinal tumors in mice. Cancer Prev. Res. 2008, 1:233-240.
47. Eads C.A., Danenberg K.D., Kawakami K., Saltz L.B., Danenberg P.V., Laird P.W. CpG island hypermethylation in human colorectal tumors is not associated with DNA methyltransferase overexpression. Cancer Res. 1999, 59:2302-2306.
48. Etoh T., Kanai Y., Ushijima S., Nakagawa T., Nakanishi Y., Sasako M., Kitano S., Hirohashi S. Increased DNA methyltransferase 1 (DNMT1) protein expression correlates significantly with poorer tumor differentiation and frequent DNA hypermethylation of multiple CpG islands in gastric cancers. Am. J. Pathol. 2004, 164:689-699.
49. Rahman M.M., Qian Z.R., Lu Wang E., Yoshimoto K., Nakasono M., Sultana R., Yoshida T., Hayashi T., Haba R., Ishida M. DNA methyltransferases 1, 3a, and 3b overexpression and clinical significance in gastroenteropancreatic neuroendocrine tumors. Human pathol. 2010, 41:1069-1078.
50. He S.S., Wang F., Yang L.J., Guo C.Y., Wan R., Ke A.W., Xu L., Hu G.Y., Xu X.F., Shen J. Expression of DNMT1 and DNMT3a Are Regulated by GLI1 in Human Pancreatic Cancer. PloS One 2011, 6:e27684.
51. Oghamian S., Sodir N.M., Bashir M.U., Shen H., Cullins A.E., Carroll C.A., Kundu P., Shibata D., Laird P.W. Reduction of pancreatic acinar cell tumor multiplicity in Dnmt1 hypomorphic mice. Carcinogenesis 2011, 32:829-835.
52. Robertson K.D. DNA methylation, methyltransferases, and cancer. Oncogene 2001, 20:3139-3155.
53. K. Motamed, V. Trieu, SPARC Anti-inflammatory activity and uses thereof, in, Google Patents, 2009.
54. Fratta E., Sigalotti L., Covre A., Parisi G., Danielli R., Marie Nicolay H.J., Coral S., Maio M. Epigenetic mechanisms in cancer formation and progression. Cancer Epigenet. 2011, 253-298.
55. Jones P.A., Baylin S.B. The fundamental role of epigenetic events in cancer. Nat. Rev. Gen. 2002, 3:415-428.
56. Shen L., Kondo Y., Ahmed S., Boumber Y., Konishi K., Guo Y., Chen X., Vilaythong J.N., Issa J.P.J. Drug sensitivity prediction by CpG island methylation profile in the NCI-60 cancer cell line panel. Cancer Res. 2007, 67:11335-11343.
57. Messick C.A., Sanchez J., DeJulius K.L., Church J.M., Kalady M.F. Genetic and molecular diversity of colon cancer hepatic metastases. Surgery 2009, 146:227-231.
58. Toyota M., Ahuja N., Suzuki H., Itoh F., Ohe-Toyota M., Imai K., Baylin S.B., Issa J.P.J. Aberrant methylation in gastric cancer associated with the CpG island methylator phenotype. Cancer Res. 1999, 59:5438-5442.
59. An C., Choi I.S., Yao J.C., Worah S., Xie K., Mansfield P.F., Ajani J.A., Rashid A., Hamilton S.R., Wu T.T. Prognostic significance of CpG island methylator phenotype and microsatellite instability in gastric carcinoma. Clin. Cancer Res.: Official J. Am. Associat. Cancer Res. 2005, 11:656-663.
60. Zhang C., Guo X., Zhang L., Lu Z., Ma N., Cheng Y., Shen F., Zhang B., Wu M., Wei L. Methylation-related silencing of p14ARF gene correlates with telomerase activity and mRNA expression of human telomerase reverse transcriptase in hepatocellular carcinoma. J. Surg. Oncol. 2008, 98:462-468.
61. Arnold C.N., Nagasaka T., Goel A., Scharf I., Grabowski P., Sosnowski A., Schmitt-Gräff A., Boland C.R., Arnold R., Blum H.E. Molecular characteristics and predictors of survival in patients with malignant neuroendocrine tumors. Int. J. Cancer 2008, 123:1556-1564.
62. Xiong Z., Laird P.W. COBRA: a sensitive and quantitative DNA methylation assay. Nucleic Acids Res. 1997, 25:2532-2534.
63. Yang L., Lin C., Liu W., Zhang J., Ohgi K.A., Grinstein J.D., Dorrestein P.C., Rosenfeld M.G. NcRNA-and Pc2 methylation-dependent gene relocation between nuclear structures mediates gene activation programs. Cell 2011, 147:773-788.
64. Rajendran P., Delage B., Dashwood W.M., Yu T.W., Wuth B., Williams D.E., Ho E., Dashwood R.H. Histone deacetylase turnover and recovery in sulforaphane-treated colon cancer cells: competing actions of 14-3-3 and Pin1 in HDAC3/SMRT corepressor complex dissociation/reassembly. Mol. Cancer 2011, 10:68-86.
65. Saikawa Y., Sugiura T., Toriumi F., Kubota T., Suganuma K., Isshiki S., Otani Y., Kumai K., Kitajima M. Cyclooxygenase-2 gene induction causes CDDP resistance in colon cancer cell line, HCT-15. Anticancer Res. 2004, 24:2723-2728.
66. Schneider-Stock R., Boltze C., Lasota J., Peters B., Corless C.L., Ruemmele P., Terracciano L., Pross M., Insabato L., Di Vizio D. Loss of p16 protein defines high-risk patients with gastrointestinal stromal tumors: a tissue microarray study. Clin. Cancer Res. 2005, 11:638-645.
67. Fukushima N., Sato N., Ueki T., Rosty C., Walter K.M., Wilentz R.E., Yeo C.J., Hruban R.H., Goggins M. Aberrant methylation of Preproenkephalin and p16 genes in Pancreatic Intraepithelial Neoplasia and Pancreatic Ductal Adenocarcinoma. Am. J. Pathol. 2002, 160:1573-1581.
68. Flis S., Gnyszka A., Misiewicz-Krzemińska I. J. SPLAWIńSKI, Decytabine enhances cytotoxicity induced by oxaliplatin and 5-fluorouracil in the colorectal cancer cell line Colo-205. Cancer Cell Int. 2009, 27:1-10.
69. Andersen J.B., Factor V.M., Marquardt J.U., Raggi C., Lee Y.H., Seo D., Conner E.A., Thorgeirsson S.S. An integrated genomic and pharmacoepigenomic approach predicts therapeutic response of zebularine in human liver cancer. Sci. Transl. Med. 2010, 2:54ra77.
70. Neureiter D., Zopf S., Leu T., Dietze O., Hauser-Kronberger C., Hahn E.G., Herold C., Ocker M. Apoptosis, proliferation and differentiation patterns are influenced by Zebularine and SAHA in pancreatic cancer models. Scand. J. Gastroenterol. 2007, 42:103-116.
71. Yoo C.B., Valente R., Congiatu C., Gavazza F., Angel A., Siddiqui M.A., Jones P.A., McGuigan C., Marquez V.E. Activation of p16 gene silenced by DNA methylation in cancer cells by phosphoramidate derivatives of 2'-deoxyzebularine. J. Med. Chem. 2008, 51:7593-7601.
72. Hong S.M., Omura N., Vincent A., Li A., Knight S., Yu J., Hruban R.H., Goggins M. Genome-wide CpG island profiling of intraductal papillary mucinous neoplasms of the pancreas. Clin. Cancer Res. 2012, 18:700-712.
73. Laird P.W. The power and the promise of DNA methylation markers. Nat. Rev. Cancer 2003, 3:253-266.
74. Issa J.P. CpG island methylator phenotype in cancer. Nat. Rev. Cancer 2004, 4:988-993.
75. Egger G., Liang G., Aparicio A., Jones P.A. Epigenetics in human disease and prospects for epigenetic therapy. Nature 2004, 429:457-463.
76. Estella C., Herrer I., Atkinson S.P., Quiñonero A., Martínez S., Pellicer A., Simón C. Inhibition of histone deacetylase activity in human endometrial stromal cells promotes extracellular matrix remodelling and limits embryo invasion. PloS One 2012, 7:e30508.
77. Schutte M., Hruban R.H., Geradts J., Maynard R., Hilgers W., Rabindran S.K., Moskaluk C.A., Hahn S.A., Schwarte-Waldhoff I., Schmiegel W. Abrogation of the Rb/p16 tumor-suppressive pathway in virtually all pancreatic carcinomas. Cancer Res. 1997, 57:3126.
78. Vincent A., Omura N., Hong S.M., Jaffe A., Eshleman J., Goggins M. Genome-wide analysis of promoter methylation associated with gene expression profile in pancreatic adenocarcinoma. Clin. Cancer Res. 2011, 17:4341.
79. Hong S.M., Park J.Y., Hruban R.H., Goggins M. Molecular signatures of pancreatic cancer. Arch. Pathol. Lab. Med. 2011, 135:716-727.
80. Hruban R.H., Adsay N.V., Albores-Saavedra J., Compton C., Garrett E.S., Goodman S.N., Kern S.E., Klimstra D.S., Kloppel G., Longnecker D.S., Luttges J., Offerhaus G.J. Pancreatic intraepithelial neoplasia: a new nomenclature and classification system for pancreatic duct lesions. Am. J. Surg. Pathol. 2001, 25:579-586.
81. Hruban R.H., Takaori K., Klimstra D.S., Adsay N.V., Albores-Saavedra J., Biankin A.V., Biankin S.A., Compton C., Fukushima N., Furukawa T. An illustrated consensus on the classification of pancreatic intraepithelial neoplasia and intraductal papillary mucinous neoplasms. Am. J. Surg. Pathol. 2004, 28:977-987.
82. Chen R.Z., Pettersson U., Beard C., Jackson-Grusby L., Jaenisch R. DNA hypomethylation leads to elevated mutation rates. Nature 1998, 395:89-93.
83. Gaudet F., Hodgson J.G., Eden A., Jackson-Grusby L., Dausman J., Gray J.W., Leonhardt H., Jaenisch R. Induction of tumors in mice by genomic hypomethylation. Science 2003, 300:489-492.
84. Ehrlich M. DNA methylation in cancer: too much, but also too little. Oncogene 2002, 21:5400-5413.
85. Rosty C., Christa L., Kuzdzal S., Baldwin W.M., Zahurak M.L., Carnot F., Chan D.W., Canto M., Lillemoe K.D., Cameron J.L. Identification of hepatocarcinoma-intestine-pancreas/pancreatitis-associated protein I as a biomarker for pancreatic ductal adenocarcinoma by protein biochip technology. Cancer Res. 2002, 62:1868-1875.
86. Issa J.P. Colon cancer: it's CIN or CIMP. Clin. Cancer Res. 2008, 14:5939-5940.
87. Toyota M., Ahuja N., Ohe-Toyota M., Herman J.G., Baylin S.B., Issa J.P.J. CpG island methylator phenotype in colorectal cancer. Proc. Natl. Acad. Sci. 1999, 96:8681-8686.
88. van Engeland M., Derks S., Smits K.M., Meijer G.A., Herman J.G. Colorectal cancer epigenetics: complex simplicity. J. Clin. Oncol. 2011, 29:1382-1391.
89. Laird P.W., Jackson-Grusby L., Fazeli A., Dickinson S.L., Jung W.E., Li E., Weinberg R.A., Jaenisch R. Suppression of intestinal neoplasia by DNA hypomethylation. Cell 1995, 81:197-205.
90. Yamada Y., Jackson-Grusby L., Linhart H., Meissner A., Eden A., Lin H., Jaenisch R. Opposing effects of DNA hypomethylation on intestinal and liver carcinogenesis. Proc. Natl. Acad. Sci. 2005, 102:13580-13585.
91. Nagaraju G.P.C., Sharma D. Anti-cancer role of SPARC, an inhibitor of adipogenesis. Cancer Treat. Rev. 2011, 37:559-566.
92. Brabender J., Lord R., Metzger R., Park J., Salonga D., Danenberg K., Danenberg P., Hölscher A., Schneider P. Differential SPARC mRNA expression in Barrett's oesophagus. Br. J. Cancer 2003, 89:1508-1512.
93. Le Bail B., Faouzi S., Boussarie L., Guirouilh J., Blanc J.F., Carles J., Bioulac-Sage P., Balabaud C., Rosenbaum J. Osteonectin/SPARC is overexpressed in human hepatocellular carcinoma. J. Pathol. 1999, 189:46-52.
94. Wang L., Yang M., Shan L., Qi L., Chai C., Zhou Q., Yao K., Wu H., Sun W. The role of SPARC protein expression in the progress of gastric cancer. Pathol. Oncol. Res. 2012, 18:697-702.
95. Wang C., Lin K., Chen S., Chan Y., Hsueh S. Overexpression of SPARC gene in human gastric carcinoma and its clinic-pathologic significance. Br. J. Cancer 2004, 91:1924-1930.
96. Atorrasagasti C., Malvicini M., Aquino J.B., Alaniz L., Garcia M., Bolontrade M., Rizzo M., Podhajcer O.L., Mazzolini G. Overexpression of SPARC obliterates the in vivo tumorigenicity of human hepatocellular carcinoma cells. Int. J. Cancer 2010, 126:2726-2740.
97. Chan J.M., Ho S.H., Tai I.T. Secreted protein acidic and rich in cysteine-induced cellular senescence in colorectal cancers in response to irinotecan is mediated by P53. Carcinogenesis 2010, 31:812-819.
98. Porte H., Triboulet J.P., Kotelevets L., Carrat F., Prévot S., Nordlinger B., DiGioia Y., Wurtz A., Comoglio P., Gespach C. Overexpression of stromelysin-3, BM-40/SPARC, and MET genes in human esophageal carcinoma: implications for prognosis. Clin. Cancer Res. 1998, 4:1375-1382.
99. Puolakkainen P.A., Brekken R.A., Muneer S., Sage E.H. Enhanced growth of pancreatic tumors in SPARC-null mice is associated with decreased deposition of extracellular matrix and reduced tumor cell apoptosis. Mol. Cancer Res. 2004, 2:215-224.
100. Said N., Socha M., Olearczyk J., Elmarakby A., Imig J., Motamed K. Normalization of the ovarian cancer microenvironment by SPARC. Mol. Cancer Res. 2007, 5:1015-1030.
101. Sato N., Fukushima N., Maehara N., Matsubayashi H., Koopmann J., Su G., Hruban R., Goggins M. SPARC/osteonectin is a frequent target for aberrant methylation in pancreatic adenocarcinoma and a mediator of tumor-stromal interactions. Oncogene 2003, 22:5021-5030.
102. Tai I., Dai M., Owen D., Chen L. Genome-wide expression analysis of therapy-resistant tumors reveals SPARC as a novel target for cancer therapy. J. Clin. Invest. 2005, 115:1492-1502.
103. Chlenski A., Liu S., Crawford S., Volpert O., DeVries G., Evangelista A., Yang Q., Salwen H., Farrer R., Bray J. SPARC is a key Schwannian-derived inhibitor controlling neuroblastoma tumor angiogenesis. Cancer Res. 2002, 62:7357-7363.
104. DiMartino J., Lacayo N., Varadi M., Li L., Saraiya C., Ravindranath Y., Yu R., Sikic B., Raimondi S., Dahl G. Low or absent SPARC expression in acute myeloid leukemia with MLL rearrangements is associated with sensitivity to growth inhibition by exogenous SPARC protein. Leukemia 2006, 20:426-432.
105. Arnold S., Mira E., Muneer S., Korpanty G., Beck A., Holloway S., Manes S., Brekken R. Forced expression of MMP9 rescues the loss of angiogenesis and abrogates metastasis of pancreatic tumors triggered by the absence of host SPARC. Exp. Biol. Med. 2008, 233:860-873.
106. Kupprion C., Motamed K., Sage E. SPARC (BM-40, osteonectin) inhibits the mitogenic effect of vascular endothelial growth factor on microvascular endothelial cells. J. Biol. Chem. 1998, 273:29635-29640.
107. Raines E., Lane T., Iruela-Arispe M., Ross R., Sage E.H. The extracellular glycoprotein SPARC interacts with platelet-derived growth factor (PDGF)-AB and -BB and inhibits the binding of PDGF to its receptors. Proc. Natl. Acad. Sci. 1992, 89:1281-1285.
108. Francki A., Bradshaw A., Bassuk J. SPARC regulates the expression of collagen type I and transforming growth factor-beta1 in mesangial cells. J. Biol. Chem. 1999, 274:32145-32152.
109. Lau C., Poon R., Cheung S., Yu W., Fan S. SPARC and Hevin expression correlate with tumour angiogenesis in hepatocellular carcinoma. J. Pathol. 2006, 210:459-468.
110. Shankavaram U., DeWitt D., Funk S., Sage E., Wahl L. Regulation of human monocyte matrix metalloproteinases by SPARC. J. Cellu. Physiol. 1998, 173:327-334.
111. Said N., Motamed K. Absence of host-secreted protein acidic and rich in cysteine (SPARC) augments peritoneal ovarian carcinomatosis. Am. J. Pathol. 2005, 167:1739-1752.
112. Tai I.T., Dai M., Owen D.A., Chen L.B. Genome-wide expression analysis of therapy-resistant tumors reveals SPARC as a novel target for cancer therapy. J. Clin. Invest. 2005, 115:1492-1502.
113. Yiu G.K., Chan W.Y., Ng S.W., Chan P.S., Cheung K.K., Berkowitz R.S., Mok S.C. SPARC (secreted protein acidic and rich in cysteine) induces apoptosis in ovarian cancer cells. Am. J. Pathol. 2001, 159:609-622.
114. Tang M.J., Tai I.T. A novel interaction between procaspase 8 and SPARC enhances apoptosis and potentiates chemotherapy sensitivity in colorectal cancers. J. Biol. Chem. 2007, 282:34457-34467.
115. Taghizadeh F., Tang M.J., Tai I.T. Synergism between vitamin D and secreted protein acidic and rich in cysteine-induced apoptosis and growth inhibition results in increased susceptibility of therapy-resistant colorectal cancer cells to chemotherapy. Mol. cancer Ther. 2007, 6:309-317.
116. Yin J., Chen G., Liu Y., Liu S., Wang P., Wan Y., Wang X., Zhu J., Gao H. Downregulation of SPARC expression decreases gastric cancer cellular invasion and survival. J. Exp. Clin. Cancer Res. 2010, 29:59-67.
117. Yang E., Kang H.J., Koh K.H., Rhee H., Kim N.K., Kim H. Frequent inactivation of SPARC by promoter hypermethylation in colon cancers. Int. J. Cancer 2007, 121:567-575.
118. Cheetham S., Tang M., Mesak F., Kennecke H., Owen D., Tai I. SPARC promoter hypermethylation in colorectal cancers can be reversed by 5-Aza-2' deoxycytidine to increase SPARC expression and improve therapy response. Br. J. Cancer 2008, 98:1810-1819.
119. Junnila S., Kokkola A., Mizuguchi T., Hirata K., Karjalainen-Lindsberg M.L., Puolakkainen P., Monni O. Gene expression analysis identifies over-expression of CXCL1, SPARC, SPP1, and SULF1 in gastric cancer. Genes, Chromosomes Cancer 2010, 49:28-39.
120. Infante J.R., Matsubayashi H., Sato N., Tonascia J., Klein A.P., Riall T.A., Yeo C., Iacobuzio-Donahue C., Goggins M. Peritumoral fibroblast SPARC expression and patient outcome with resectable pancreatic adenocarcinoma. J. Clin. Oncol. 2007, 25:319-325.
121. Arnold S.A., Rivera L.B., Miller A.F., Carbon J.G., Dineen S.P., Xie Y., Castrillon D.H., Sage E.H., Puolakkainen P., Bradshaw A.D. Lack of host SPARC enhances vascular function and tumor spread in an orthotopic murine model of pancreatic carcinoma. Dis. Model. Mech. 2010, 3:57-72.
122. Gao A., Zuo X., Liu Q., Lu X., Guo W., Tian L. Methylation of PARP-1 promoter involved in the regulation of benzene-induced decrease of PARP-1 mRNA expression. Toxicol. Lett. 2010, 195:114-118.
123. Sova P., Feng Q., Geiss G., Wood T., Strauss R., Rudolf V., Lieber A., Kiviat N. Discovery of novel methylation biomarkers in cervical carcinoma by global demethylation and microarray analysis. Cancer Epidemiol. Biomarkers Prev. 2006, 15:114-123.
124. Yang X., Seto E. HATs and HDACs: from structure, function and regulation to novel strategies for therapy and prevention. Oncogene 2007, 26:5310-5318.
125. Massi D., Franchi A., Borgognoni L., Reali U.M., Santucci M. Osteonectin expression correlates with clinical outcome in thin cutaneous malignant melanomas. Human Pathol. 1999, 30:339-344.
126. Yamanaka M., Kanda K., Li N.C., Fukumori T., Oka N., Kanayama H.O., Kagawa S. Analysis of the gene expression of SPARC and its prognostic value for bladder cancer. J. Urol. 2001, 166:2495-2499.
127. Yamashita K., Upadhay S., Mimori K., Inoue H., Mori M. Clinical significance of secreted protein acidic and rich in cystein in esophageal carcinoma and its relation to carcinoma progression. Cancer 2003, 97:2412-2419.
128. Che Y., Luo A., Wang H., Qi J., Guo J., Liu Z. The differential expression of SPARC in esophageal squamous cell carcinoma. Int. J. Mol. Med. 2006, 17:1027-1033.
129. Kim S.M., Park Y.Y., Park E.S., Cho J.Y., Izzo J.G., Zhang D., Kim S.B., Lee J.H., Bhutani M.S., Swisher S.G. Prognostic biomarkers for esophageal adenocarcinoma identified by analysis of tumor transcriptome. PloS One 2010, 5:e15074.
130. Matsubara N. Epigenetic regulation and colorectal cancer. Dis. Colon Rectum 2012, 55:96-104.
131. González C.A., Agudo A. Carcinogenesis, prevention and early detection of gastric cancer: where we are and where we should go. Int. J. Cancer 2012, 130:745-753.
132. Nagasaka T., Tanaka N., Cullings H.M., Sun D.S., Sasamoto H., Uchida T., Koi M., Nishida N., Naomoto Y., Boland C.R. Analysis of fecal DNA methylation to detect gastrointestinal neoplasia. J. Natl. Cancer Inst. 2009, 101:1244-1258.
133. Caffarelli E., Filetici P. Epigenetic regulation in cancer development. Front. Biosci. 2011, 17:2682-2694.
134. Sato N., Fukushima N., Maitra A., Matsubayashi H., Yeo C.J., Cameron J.L., Hruban R.H., Goggins M. Discovery of novel targets for aberrant methylation in pancreatic carcinoma using high-throughput microarrays. Cancer Res. 2003, 63:3735-3742.
135. Sato N., Matsubayashi H., Abe T., Fukushima N., Goggins M. Epigenetic down-regulation of CDKN1C/p57KIP2 in pancreatic ductal neoplasms identified by gene expression profiling. Clin. Cancer Res. 2005, 11:4681-4688.
136. Müller H.M., Oberwalder M., Fiegl H., Morandell M., Goebel G., Zitt M., Mühlthaler M., Öfner D., Margreiter R., Widschwendter M. Methylation changes in faecal DNA: a marker for colorectal cancer screening?. Lancet 2004, 363:1283-1285.
137. Glöckner S.C., Dhir M., Yi J.M., McGarvey K.E., Van Neste L., Louwagie J., Chan T.A., Kleeberger W., de Bruïne A.P., Smits K.M. Methylation of TFPI2 in stool DNA: a potential novel biomarker for the detection of colorectal cancer. Cancer Res. 2009, 69:4691-4699.
138. Melotte V., Lentjes M.H.F.M., van den Bosch S.M., Hellebrekers D.M.E.I., de Hoon J.P.J., Wouters K.A.D., Daenen K.L.J., Partouns-Hendriks I.E.J.M., Stessels F., Louwagie J. N-Myc downstream-regulated gene 4 (NDRG4): a candidate tumor suppressor gene and potential biomarker for colorectal cancer. J. Natl. Cancer Inst. 2009, 101:916-927.
139. Modiano N., Gerson L.B. Barrett's esophagus: incidence, etiology, pathophysiology, prevention and treatment. Ther. Clin. Risk Manag. 2007, 3:1035-1145.
140. Robert M.F., Morin S., Beaulieu N., Gauthier F., Chute I.C., Barsalou A., MacLeod A.R. DNMT1 is required to maintain CpG methylation and aberrant gene silencing in human cancer cells. Nat. Genet. 2002, 33:61-65.
141. Su L.J. Diet, epigenetics, and cancer. Methods Mol. Biol. 2012, 863:377-393.
142. Liu Z., Xie Z., Jones W., Pavlovicz R.E., Liu S., Yu J., Li P., Lin J., Fuchs J.R., Marcucci G. Curcumin is a potent DNA hypomethylation agent. Bioorg. Med. Chem. Lett. 2009, 19:706-709.
143. Yamaki H., Nakajima M., Shimotohno K.W., Tanaka N. Molecular basis for the actions of Hsp90 inhibitors and cancer therapy. J. Antibiot. 2011, 64:635-644.
144. Ganesan A., Nolan L., Crabb S., Packham G. Epigenetic therapy: histone acetylation, DNA methylation and anti-cancer drug discovery. Curr. Cancer Drug Targets 2009, 9:963-981.
145. Karpf A.R. Epigenomic reactivation screening to identify genes silenced by DNA hypermethylation in human cancer. Curr. Opin. Mol. Ther. 2007, 9:231-241.